Histopathological, molecular, clinical and radiological characterization of rosette-forming glioneuronal tumor in the central nervous system
Metrics: PDF 562 views | HTML 1829 views | ?
Chenlong Yang1,2,3, Jingyi Fang4, Guang Li5, Shaowu Li6, Tingting Ha7, Jiangfei Wang2,3, Bao Yang2,3, Jun Yang2,3 and Yulun Xu2,3
1Department of Orthopedics, Peking University Third Hospital, Haidian District, Beijing 100191, China
2Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Dongcheng District, Beijing 100050, China
3China National Clinical Research Center for Neurological Diseases (NCRC-ND), Dongcheng District, Beijing 100050, China
4Department of Neuro-pathology, Beijing Neurosurgical Institute, Capital Medical University, Dongcheng District, Beijing 100050, China
5Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Dongcheng District, Beijing 100050, China
6Department of Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Dongcheng District, Beijing 100050, China
7Department of Radiology, Peking University Shougang Hospital, Shijingshan District, Beijing 100144, China
Yulun Xu, email: email@example.com
Keywords: rosette-forming glioneuronal tumor; brain tumor; central nervous system; spinal cord tumor; treatment
Received: August 31, 2017 Accepted: October 29, 2017 Published: November 24, 2017
Objective: A rosette-forming glioneuronal tumor (RGNT) is a rare entity originally described in the fourth ventricle. Recently, RGNTs occurring in extraventricular sites and those with malignant behaviors have been reported. The purpose of this study was to analyze the clinicoradiological and histopathological features, therapeutic strategies, and outcomes of RGNTs.
Methods: We enrolled 38 patients diagnosed with RGNTs pathologically between August 2009 and June 2016. CT and MRI, including diffusion-weighted imaging and spectroscopy, were performed. The surgical treatment and histopathological and molecular features were assessed. Additionally, we searched the relevant literatures and performed a pooled analysis of individual patient data. The potential risk factors of prognosis were analyzed.
Results: Our case series included 22 male and 16 female patients, with a mean age of 25.9 years. RGNTs involved the fourth ventricle (26.3%), cerebella (34.2%), supratentorial ventricular system (13.2%), spinal cord (10.5%), temporal lobe (10.5%), thalamus (7.9%), brain stem (7.9%), frontal lobe (5.3%), pineal region (5.3%), suprasellar region (2.6%), and basal ganglia (2.6%). Statistical analyses showed that pediatric age, purely solid appearance of the tumor, and inadequate resection (only partial removal or biopsy) were risk factors associated with progression events. Patients with subtotal resection appeared to do as well as those with gross total resection.
Conclusions: RGNTs can occur nearly anywhere in the CNS, at both supratentorial and infratentorial sites. Maximal safe surgical resection should be emphasized for treatment; whilst aggressive resection with the goal of complete resection may be unnecessary.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.